Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
about
Adjuvant radiotherapy following radical prostatectomy for prostate cancerAdjuvant radiotherapy following radical prostatectomy for prostate cancerAdjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialRadiation Therapy after Radical Prostatectomy: Implications for CliniciansGaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of LifeContemporary Management of Prostate CancerIntegrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?Robotic-Assisted Laparoscopic Radical ProstatectomyPatient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision makingDiscovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyAdjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical ProstatectomyAdjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists.Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapyVariation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience.Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794Testing the Assessment of New Radiation Oncology Technology and Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques.Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancerIdentification of men with the highest risk of early disease recurrence after radical prostatectomyProstate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007.Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsPrognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomyMultimodal approaches to high-risk prostate cancer.Role of radical prostatectomy for high-risk prostate cancer.Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience.Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy.Current status of radical prostatectomy for high-risk prostate cancer.Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trialEarly hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
P2860
Q24234347-8F0A89A7-318A-4929-993A-15B95737AC2AQ24242552-F6A18EEC-3793-4BEE-8D91-CA498789C2D7Q24605205-9F53ED23-19DD-4823-8FAE-C02A03D1BEE1Q26744531-0B0F170C-45AC-4EA0-9390-0FC4F7756812Q26751574-42208BE3-44EB-404B-A2B9-0167C191970FQ26767456-24F9DE2E-24B5-4D82-91B3-119A007F6050Q26777128-C86C9C3B-4637-4723-9E9A-1D92A61B11C6Q26782257-DA15A878-6AC3-413E-8FB2-DE94EFFE793BQ26852751-2A7B1E57-70FD-4419-A9C3-7D88442F5D5AQ28534277-F053E3F6-2D74-4687-94C2-A97D69B67794Q28541950-2926FBA2-6533-4092-92E7-582239436000Q28554583-148615F6-A2F1-41DE-86E7-5B4324D101D2Q30278648-22DF193E-A51F-4FE8-A608-AD5301129FFAQ30300626-2333D3FE-F5C4-44CF-90BE-437F76FF6CBEQ30371634-6160117F-BC41-4ADE-8E00-16029C2C12C0Q30385364-6A4A3D8E-8EFE-436C-8482-8633F9EF18C9Q30405851-2C75C2A6-66FE-449D-9512-C83412927CF3Q30413727-49ED2A8C-ABCA-489D-B5FB-FD967D1985ACQ33317042-150C51B4-B132-441D-ABFC-E1880F5D3291Q33373839-707C223E-999D-4F78-A6D1-C026DC9F7E42Q33377809-57577F8D-5E63-4DE1-AE45-EC40A86CD147Q33390727-49ADC807-8B13-42BE-9319-52F2B99CC28CQ33669456-EFB75F12-DBA8-429C-B9AF-807778E78C97Q33705993-75C663E6-8130-4968-BEF2-FDE5386047EFQ33710312-FA8D1B05-748E-42EA-9702-58F8B6EE4EF7Q33754012-10D34BDF-BC85-44A1-A79D-E82949F3EE66Q33761075-27085794-9D4A-4753-84F0-9D351205244CQ33825388-3E9AADFE-1BAB-4BE3-A1B4-DC2B99F34158Q33887010-E65348EF-DEB3-4918-845B-7BDCFC81A33FQ33939310-57DA1C57-D88C-45E5-AAE7-787BAF152BACQ34013808-F7A035BB-2DF7-4F86-8A4F-A0365B7367BDQ34091402-3F626E53-EC3B-4BD6-B6F7-D238C1D2C1D5Q34111597-FD30181F-E1A9-40D8-BAF5-87A3E3726956Q34139187-C6E46836-8DCE-4FBF-8A5B-61AEE6319FE1Q34206798-654BC56A-B25B-426E-96FA-DE213B736FCDQ34325452-0528B254-B532-4A6D-B4A9-59F9B64A7BEAQ34325482-55A0A89C-B196-4C6B-8653-2E1C884BA72FQ34346841-593A0B0F-C946-4D19-B70D-0E36F6B21220Q34462816-5FD8FDD4-D758-4AA7-A9EE-3C44E5D9E644Q34725046-285723E5-6E95-4F7B-B1CD-0AB19B6E9194
P2860
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adjuvant radiotherapy for path ...... : a randomized clinical trial.
@en
type
label
Adjuvant radiotherapy for path ...... : a randomized clinical trial.
@en
prefLabel
Adjuvant radiotherapy for path ...... : a randomized clinical trial.
@en
P2093
P356
P1476
Adjuvant radiotherapy for path ...... : a randomized clinical trial.
@en
P2093
Catherine M Tangen
Dean Troyer
E David Crawford
Edith Canby-Hagino
Edward Messing
Gary Miller
Gregory Swanson
Ian M Thompson
Jeffrey Forman
Jorge Paradelo
P304
P356
10.1001/JAMA.296.19.2329
P407
P577
2006-11-01T00:00:00Z